Industry Symposium: Innovative oral treatment options for patients: HR+/HER2- MBC or gBRCA-Mutated TNBC and HR+/HER2- MBC
Supported by Pfizer

Pfizer

Thursday, September 5, 2019
12:45-13:45
Hall B

Innovative oral treatment options for patients: HR+/HER2- MBC or gBRCA-Mutated TNBC and  HR+/HER2- MBC
David C. Molthrop, USA